| pubmed-article:3013033 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3013033 | lifeskim:mentions | umls-concept:C0686347 | lld:lifeskim |
| pubmed-article:3013033 | lifeskim:mentions | umls-concept:C0556096 | lld:lifeskim |
| pubmed-article:3013033 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:3013033 | pubmed:dateCreated | 1986-7-23 | lld:pubmed |
| pubmed-article:3013033 | pubmed:abstractText | Preclinical and clinical observations suggest that enhancement of prostaglandin activity inhibits catecholamine release and may have antidyskinetic effects. A double-blind therapeutic trial with prostaglandin precursor essential fatty acids was conducted in 16 patients with tardive dyskinesia. No beneficial effects were seen. | lld:pubmed |
| pubmed-article:3013033 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3013033 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3013033 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:3013033 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3013033 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3013033 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3013033 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3013033 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:3013033 | pubmed:issn | 0002-953X | lld:pubmed |
| pubmed-article:3013033 | pubmed:author | pubmed-author:RotrosenJJ | lld:pubmed |
| pubmed-article:3013033 | pubmed:author | pubmed-author:RubinsteinMM | lld:pubmed |
| pubmed-article:3013033 | pubmed:author | pubmed-author:JordanBB | lld:pubmed |
| pubmed-article:3013033 | pubmed:author | pubmed-author:WolkinAA | lld:pubmed |
| pubmed-article:3013033 | pubmed:author | pubmed-author:PeselowEE | lld:pubmed |
| pubmed-article:3013033 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3013033 | pubmed:volume | 143 | lld:pubmed |
| pubmed-article:3013033 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3013033 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3013033 | pubmed:pagination | 912-4 | lld:pubmed |
| pubmed-article:3013033 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:3013033 | pubmed:meshHeading | pubmed-meshheading:3013033-... | lld:pubmed |
| pubmed-article:3013033 | pubmed:meshHeading | pubmed-meshheading:3013033-... | lld:pubmed |
| pubmed-article:3013033 | pubmed:meshHeading | pubmed-meshheading:3013033-... | lld:pubmed |
| pubmed-article:3013033 | pubmed:meshHeading | pubmed-meshheading:3013033-... | lld:pubmed |
| pubmed-article:3013033 | pubmed:meshHeading | pubmed-meshheading:3013033-... | lld:pubmed |
| pubmed-article:3013033 | pubmed:meshHeading | pubmed-meshheading:3013033-... | lld:pubmed |
| pubmed-article:3013033 | pubmed:meshHeading | pubmed-meshheading:3013033-... | lld:pubmed |
| pubmed-article:3013033 | pubmed:meshHeading | pubmed-meshheading:3013033-... | lld:pubmed |
| pubmed-article:3013033 | pubmed:meshHeading | pubmed-meshheading:3013033-... | lld:pubmed |
| pubmed-article:3013033 | pubmed:year | 1986 | lld:pubmed |
| pubmed-article:3013033 | pubmed:articleTitle | Essential fatty acid supplementation in tardive dyskinesia. | lld:pubmed |
| pubmed-article:3013033 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3013033 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:3013033 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| pubmed-article:3013033 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| pubmed-article:3013033 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
